Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial

Jie Wang; Yong Li; Yan-li Tang; Hong-sheng Lin; Xin-fang Wu; Jie Liu

doi:10.1007/s11655-013-1449-z

Your Location：

Home >

Browse articles >

Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial

OriginalPaper | Updated：2021-08-27

- Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial
- Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial
- 中国结合医学杂志（英文版） 2013年19卷第5期页码：340-346
- Affiliations：
  
  Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by Chinese Ministry of Science and Technology (No. 2008ZX10005-004)
- DOI：10.1007/s11655-013-1449-z
  中图分类号：
- 纸质出版日期：2013，
  
  网络出版日期：2013-3-15，
Scan for full text
Wang, J., Li, Y., Tang, Yl. et al. Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial., Chin. J. Integr. Med. 19, 340–346 (2013). https://doi.org/10.1007/s11655-013-1449-z

Jie Wang, Yong Li, Yan-li Tang, et al. Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial[J]. Chinese Journal of Integrative Medicine, 2013,19(5):340-346.
Wang, J., Li, Y., Tang, Yl. et al. Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial., Chin. J. Integr. Med. 19, 340–346 (2013). https://doi.org/10.1007/s11655-013-1449-z DOI：

Jie Wang, Yong Li, Yan-li Tang, et al. Effect of Immune No. 2 (免疫2号方) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial[J]. Chinese Journal of Integrative Medicine, 2013,19(5):340-346. DOI： 10.1007/s11655-013-1449-z.

摘要

To observe the Immune No. 2 (免疫2号方) on the immune reconstitution in patients with human immunodeficiency virus or acquired immune deficiency syndrome (HIV/AIDS) after highly active antiretroviral therapy (HAART). A randomized

double-blind

placebo-controlled clinical trial was designed. 233 patients failing immune reconstitution after HAART were randomly divided into treatment group (116 cases) and control group (117 cases)

respectively using Immune No. 2 plus HAART and placebo combined with HAART for 6 months. CD4

CD45RA

CD45RO cell numbers

as well as the symptoms

signs and integral improvement rates were observed in order to evaluate the immune reconstitution efficiency. after the intervention for 1 month

the effective rate of the treatment group (18.97%

22/116) was significantly higher than that of the control group (9.40%

11/117) (P=0.02); 3 months after treatment

the effective rate of the treatment group (27.59%

32/116) was no difference from that of the control group (22.22%

26/117) (P=0.31); 6 months after treatment

the effective rate of the treatment group (34.48%

40/116) was significantly superior to the control group (21.37%

25/117) (P=0.02). CD4

CD45RA

CD45RO count of the treatment group was significantly higher than that of the control group (P<0.05). The total score of symptoms and signs in the treatment group was significantly lowered compared with the control group (P=0.02)

and the improvement of fatigue

muscle and joint pain

pruritus and shortness of breath in the treatment group was better than the control group (P<0.05). Immune No. 2 can effectively improve the numbers of CD4 cells and its subgroups

as well as the main clinical symptoms and signs of patients after HAART

thereby promoting the immune reconstitution.

Abstract

double-blind

placebo-controlled clinical trial was designed. 233 patients failing immune reconstitution after HAART were randomly divided into treatment group (116 cases) and control group (117 cases)

respectively using Immune No. 2 plus HAART and placebo combined with HAART for 6 months. CD4

CD45RA

CD45RO cell numbers

as well as the symptoms

signs and integral improvement rates were observed in order to evaluate the immune reconstitution efficiency. after the intervention for 1 month

the effective rate of the treatment group (18.97%

22/116) was significantly higher than that of the control group (9.40%

11/117) (P=0.02); 3 months after treatment

the effective rate of the treatment group (27.59%

32/116) was no difference from that of the control group (22.22%

26/117) (P=0.31); 6 months after treatment

the effective rate of the treatment group (34.48%

40/116) was significantly superior to the control group (21.37%

25/117) (P=0.02). CD4

CD45RA

and the improvement of fatigue

muscle and joint pain

pruritus and shortness of breath in the treatment group was better than the control group (P<0.05). Immune No. 2 can effectively improve the numbers of CD4 cells and its subgroups

as well as the main clinical symptoms and signs of patients after HAART

thereby promoting the immune reconstitution.

关键词

HIV/AIDSimmune reconstitutionImmune No. 2

Keywords

HIV/AIDSimmune reconstitutionImmune No. 2

references

Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011;117:5582–5590.

Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669–676.

Ministry of Health of the People’s Republic of China. The national HIV testing technology standard. Beijing: Chinese Center for Disease Control and Prevention;2009:5–18.

Zheng XY, ed. Guiding principle of Clinical researches on new drugs of traditional Chinese medicine. Beijing: China Medical Science Press;2002:28–31.

Wang YH, Liu Zhong S, Guan F, Wang R. Research on immunological regulation effect of Radix Panacis Quinquefolii and related preparation. Chin Arch Tradit Chin Med (Chin) 2004;22:566–567.

Zhang X, Li S. Progress on research of Chinese medicine in the treatment of AIDS. Chin J Inf TCM (Chin) 2000;7:20–22.

Guo HC, Gao JQ, Xi QY, Li XH. Progress of research of Sphaeria sinensis. J Microbiol (Chin) 2003;23:50–55.

Li TS, Carcelaine G, Debre P, Autran B. Immune reconstitution in AIDS patients during highly active antiretroviral therapies. Basic Med Sci Clin (Chin) 2001;21:6–11.

Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191:1670–1679.

Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgrò A, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20:2033–2041.

Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis 2008;46:1902–1910.

Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000;181:141–147.

Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–116.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims, draft guidance. Health Qual Life 2006;4:79.

FULL TEXT LINK

More>

浏览量

1025

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Immune reconstitution—the footing of chinese medicine treatment for acquired immunodeficiency syndrome

Randomized double-blinded and controlled clinical trial on treatment of HIV/AIDS by Zhongyan-4